[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Institut Investigacio Sanitaria Pere Virgili\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":438},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,50,79,108,138,170,203,231,262,292,324,355,386,414],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100643771","development-of-a-multidimensional-predictive-model-of-dystocic-labor-association-of-physical-condition-and-psychosocial-factors-with-the-birth-process-and-breastfeeding-success-100643771",false,"NCT07635771","Development of a Multidimensional Predictive Model of Dystocic Labor. Association of Physical Condition and Psychosocial Factors With the Birth Process and Breastfeeding Success.","Development of a Multidimensional Predictive Model of Dystocic Labor (MPM-PD): Pilot Study on the Association of Physical Condition and Psychosocial Factors With the Completion of Labor and the Success of Breastfeeding.","MPM-PD","Inclusion Criteria:\n\n* Pregnant women aged 18 years or older\n* Low-to-moderate risk pregnancy\n* Singleton pregnancy\n* Third trimester of pregnancy (\\>28 gestational weeks)\n* Understanding of the official languages\n* Acceptance and signing of the participant information sheet and informed consent form\n* Availability of an electronic device to complete the forms\n\nExclusion Criteria:\n\n* Medical contraindication for light physical activity\n* Severe cardio-respiratory or musculoskeletal pathology\n* Elective cesarean section\n* Severe fetal malformations","FEMALE","18 Years",{"count":20,"type":21},420,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn how a pregnant woman's physical fitness and emotional well-being can help predict the type of birth she will have (such as a natural vaginal birth versus a cesarean section or a birth requiring medical assistance). The study focuses on pregnant women in their third trimester (after 28 weeks of pregnancy).\n\nThe main questions the study aims to answer are:\n\n* Can simple tests of physical strength and questions about emotions (like fear of childbirth) help health professionals predict if a birth might have complications or lack of progress?\n* Do a woman's physical activity and confidence levels during pregnancy affect her ability to successfully breastfeed her baby for up to 6 months?\n\nParticipants will be asked to:\n\n* Perform two simple physical tests during a clinic visit: a hand-grip test (dynamometry test) and a test to see how many times they can stand up from a chair in 30 seconds (Chair Stand Test, CST).\n* Complete surveys about their daily physical activity (PPAQ-S), their feelings and fears regarding childbirth (WDEQ-A), and how confident they feel about handling the final stage of birth and the pushing phase (CBSEI-16).\n* Answer brief follow-up phone calls one month and six months after the birth to talk about how breastfeeding is going.",[25,26,27,28,29,30,31],"Labor and Childbirth","Labor (Obstetrics)--Complications","Hand Strength","Physical Conditioning, Human","Tocophobia","Self Efficacy","Breastfeeding",[33,34,27,35,36,29,30,31],"Labor, Obstetric","Obstetric Labor Complications","Dynamometry","Physical condition","RECRUITING","2026-06-18",{"date":40,"type":41},"2026-06-23","ACTUAL",{"date":43,"type":41},"2026-06-10",{"date":45,"type":21},"2027-12",{"name":47,"class":48},"Institut Investigacio Sanitaria Pere Virgili","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":49},"100642626","menopause-experiences-in-cultural-and-intercultural-contexts-100642626","NCT07648680","\"Menopause Experiences in Cultural and Intercultural Contexts\"","\"Menopause Experiences in Intercultural Contexts and Healthcare Professionals: A Mixed- Methods Study Protocol in Community Settings\"","VIMEC-IC","Inclusion Criteria:\n\nFor professionals:\n\n* Healthcare professional aged 18 years or older.\n* Currently working in the Primary Care setting.\n* Provide care or work with women in the climateric stage.\n* Agreement to participate and completion of the anonymous survey after providing informed consent.\n\nFor Women (Qualitative Phase):\n\n* Women aged 40 to 65 years.\n* Currently in the climacteric stage (perimenopause or postmenopause).\n* Belonging to diverse sociocultural or ethnic backgrounds.\n* Ability to communicate and provide informed consent for the individual interview.\n\nExclusion Criteria:\n\nFor porfessionals:\n\n\\*Refusal to participate in the study or incomplete electronic survey.\n\nFor Women (Qualitative Phase):\n\n* Inability to understand the study's language (Spanish or Catalan).\n* Cognitive impairment that prevents the participant from providing informed consent or participating in the interview\u002Fsurvey.\n* Refusal to participate in the study.","40 Years","65 Years",{"count":61,"type":21},25,"The climacteric period involves physical, hormonal, and emotional changes that can impact a woman's quality of life. This mixed-methods study aims to explore the perceptions and experiences of women during menopause and the influence of cultural ethnicity on their quality of life in Primary Care centers in Tarragona. The research includes a quantitative phase to assess healthcare professionals' knowledge via electronic surveys and a qualitative phase using individual interviews with women from diverse backgrounds. The goal is to identify specific needs to adapt community nursing interventions and improve health promotion and equity during the climacteric stage.",[64],"Valid MeSH Conditions",[66,67,68,69,70],"Menopause","quality of life","physical activity","Mediterranean Diet","Nursing","2026-06-12",{"date":73,"type":41},"2026-06-15",{"date":75,"type":41},"2026-04-27",{"date":77,"type":21},"2030-04-22",{"name":47,"class":48},{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":59,"enrollmentInfo":87,"targetDuration":4,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":96,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":49},"100600412","avocado-consumption-and-cellular-aging-in-breast-cancer-survivors-100600412","NCT07097155","Avocado Consumption and Cellular Aging in Breast Cancer Survivors","Effect of Daily Avocado Consumption on Cellular Aging in Female Breast Cancer Survivors: The ACCA Study","ACCA","Inclusion Criteria:\n\n* Women diagnosed with primary breast cancer in stages I, II or III;\n* 40-65 years old at screening;\n* Cancer treatment (radiotherapy and chemotherapy) completed ≥ 6 months but not more than 10 years at the time of recruitment;\n* Currently consuming less than 2 avocados per week;\n* Signed the informed consent letter.\n\nExclusion Criteria:\n\n* Metastasis;\n* Ductal carcinoma or lobular carcinoma in situ;\n* Breast cancer recurrence;\n* Cancer diagnosis other than breast cancer or non-melanoma skin cancer;\n* Body mass index ≥40kg\u002Fm2;\n* Currently pregnant or breastfeeding, or planning pregnancy in the following 6 months;\n* Allergy to latex;\n* Unwilling to consume avocado;\n* Immunodeficiency or HIV-positive status;\n* Alcohol abuse (\\>50g\u002Fday);\n* Unstable use of plant sterols, mineral supplements, use of fibre supplements, fish oil, or antioxidants in the 4 weeks prior to enrolment, or plans to change this during the study;\n* Currently participating in any other randomized controlled trial;\n* Difficulty or impossibility of an adequate follow-up;\n* Inability or unwillingness to give written informed consent or to communicate with study personnel, or illiteracy;\n* Patients with an acute infection or inflammation (e.g., pneumonia) will be allowed to participate in the study 3 months after recovery.",{"count":88,"type":21},120,"INTERVENTIONAL",[91],"NA","Women with breast cancer are at increased risk of comorbidities and premature mortality, potentially due to accelerated biological aging. Telomere attrition has been proposed as a biomarker of this process, which could be mitigated through interventions targeting behavioral factors such as diet. In recent years, avocado has drawn attention in nutritional research due to its unique nutritional profile.\n\nMain objective: To evaluate the effect of consuming one avocado per day on biological aging-measured by telomere length-in breast cancer survivors, compared to a habitual diet (less than two avocados per week). Secondary objectives include changes in telomerase activity and biomarkers of inflammation and oxidative stress. Additional objectives include classical cardiovascular disease markers (glucose metabolism, lipid profile, blood pressure); anthropometric measurements; symptoms of depression and anxiety; quality of life and fatigue; and diet quality.\n\nMethodology: A randomized controlled parallel-group trial involving 120 breast cancer survivors. Participants will be randomly assigned to either the intervention group (one avocado per day) or the control group (habitual diet with fewer than two avocados per week) and followed for 4 months. At baseline and the end of the intervention, a general questionnaire will be administered; blood and urine samples will be collected; anthropometric and blood pressure measurements will be taken; and diet, physical activity, symptoms of depression and anxiety, quality of life, and fatigue will be assessed. Mean changes from baseline to the end of the intervention in the primary outcome (telomere length) and secondary outcomes (inflammation, oxidative stress, classical cardiovascular disease markers, anthropometric measures, symptoms of depression and anxiety, quality of life, and diet) will be compared between the intervention and control groups using linear regression models.",[94,95],"Telomere Length","Breast Cancer Females",[97,98,99],"Avocado consumption","Telomere length","Breast Cancer","2026-05-07",{"date":102,"type":41},"2026-05-12",{"date":104,"type":41},"2026-01-12",{"date":106,"type":21},"2027-08",{"name":47,"class":48},{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":116,"sex":117,"minAge":118,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":89,"phases":121,"briefSummary":122,"conditions":123,"keywords":125,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":49},"100636250","computer-assisted-cognitive-stimulation-treatment-for-delirium-100636250","NCT07563244","Computer-assisted Cognitive Stimulation Treatment for Delirium","Clinical, Demographic and Genetic Factors Associated With Response to Computer-assisted Cognitive Stimulation Treatment as Part of Non-pharmacological Care in Patients With Delirium. Feasibility Study.","Delitract","Inclusion Criteria:\n\n* All patients aged 60 years or over who are admitted to the subacute care center between 15 February and 15 October 2026 and who sign the informed consent (the patient and their family or legal guardians if the patient's cognitive condition prevents them from giving consent themselves)\n\nExclusion Criteria:\n\n* Patients who, at the time of admission, meet the criteria for palliative end-of-life care.\n* Individuals under 60 years of age, to ensure sample homogeneity and reduce confounding factors.\n* Individuals with severe visual or hearing impairment or aphasia, due to the difficulty of carrying out the cognitive intervention.\n* Serious communication difficulties due to language.",true,"ALL","60 Years",{"count":120,"type":21},60,[91],"The objectives of our study are to determine whether people with delirium in a subacute care unit improve after one week with non-pharmacological therapies based on improving sleep schedules, mobility, and cognitive stimulation (such as memory, attention, orientation, among others), and to compare two groups of people who will receive slightly different therapies.\n\nWe will try to determine whether individual characteristics (such as diagnosed diseases, blood test results or genetics, gender, age, educational level, among others) influence the onset of an episode of delirium, its severity and its response to treatment.\n\nParticipants with delirium will be divided into two groups that will receive:\n\n* The non-pharmacological treatment described\n* One group will also receive a specific cognitive intervention from an occupational therapist, using a computer programme on a tablet, twice a day for one week.\n\nAfter one week, the presence and severity of delirium will be reassessed.",[124],"Delirium",[124,126,127,128,129],"Older adults","Dementia","Subacute care","Cognitive training","2026-04-24",{"date":132,"type":41},"2026-05-01",{"date":134,"type":41},"2026-02-16",{"date":136,"type":21},"2027-02-16",{"name":47,"class":48},{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":89,"phases":148,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":49},"100631769","effectiveness-of-radiofrequency-combined-with-ultrasound-for-the-treatment-of-postpartum-dyspareunia-100631769","NCT07504991","Effectiveness of Radiofrequency Combined With Ultrasound for the Treatment of Postpartum Dyspareunia","Effectiveness of Combined Monopolar Radiofrequency and Ultrasound (BTL EXILIS ULTRA 360™) for the Improvement of Dyspareunia Caused by Postpartum Scarring in Women of Childbearing Age: A Study Protoco","Inclusion Criteria:\n\n* Women of childbearing age\n* Medical history of at least one prior vaginal delivery\n* Reported persistent pain during penetrative sexual intercourse\n* Meeting the clinical criteria for dyspareunia\n* Moderate to severe pain level, defined as a score of 4 or higher on the Visual Analogue Scale (VAS 0-10)\n* Eligible patients must demonstrate a moderate to severe pain level, defined as a VAS score of 4 or higher\n* No restriction on the time elapsed between the last delivery and the current clinical diagnosis.\n\nExclusion Criteria:\n\n* Contraindications to the study treatment. Women with any medical condition that precludes the use of the study technology\n* Non-postpartum dyspareunia","50 Years",{"count":147,"type":21},34,[91],"The objective of this community-based, non-randomized, quasi-experimental study is to assess the effectiveness of BTL EXILIS technology-based on combined radiofrequency and ultrasound-in women of childbearing age from an industrialized country with a diagnosis of dyspareunia following vaginal delivery.\n\nThe primary research question is:\n\n\\- Do patients experience a resolution of pain during sexual intercourse after completing the treatment?\n\nThe researcher will compare the level of pain during intercourse-following at least one vaginal delivery involving a tear or episiotomy-before and after exposure to the BTL Exilis treatment in the same individual.\n\nParticipants:\n\n* Assessment following childbirth with perineal involvement (tear or episiotomy) and presenting with dyspareunia.\n* Verification of fulfillment of inclusion criteria.\n* Decision on whether to undergo treatment, following a briefing by the researcher on the process and the signing of the informed consent form for study participation.\n* Follow-up assessment one and a half months after completing the treatment.",[151],"Dyspareunia",[153,154,155,156,157,158,159,160,161],"vaginal delivery","dyspareunia","radiofrequency","perineum","Visual Analogue Scale","tear scar","episiotomy scar","woman","pain","2026-04-13",{"date":164,"type":41},"2026-04-16",{"date":166,"type":21},"2026-04",{"date":168,"type":21},"2026-12",{"name":47,"class":48},{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":89,"phases":179,"briefSummary":180,"conditions":181,"keywords":183,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":201,"leadSponsor":202,"locationsCount":49},"100633582","hifem-in-pospartum-high-intensity-focused-electro-magnetic-technology-100633582","NCT07528560","HIFEM in Pospartum (High Intensity Focused Electro-Magnetic Technology)","Effectiveness of HIFEM (High Intensity Focused Electro-Magnetic Technology) for Improving Pelvic Floor Muscle Tone in Postpartum Women: Study Protocol.","HIFEM","Inclusion Criteria:\n\n* Primiparous women\n* Vaginal delivery.\n* Single-fetus pregnancy \u002F Singleton pregnancy.\n* Full-term pregnancy (\\> 37 weeks of gestation).\n* Asymptomatic: No symptoms associated with pelvic floor muscle weakening, such as any type of incontinence or presence of prolapse.\n* Post-quarantine period: Between 6 and 12 weeks postpartum\n\nExclusion Criteria:\n\n* Implanted devices: Such as pacemakers, defibrillators, or neurostimulators.\n* Electronic implants.\n* Drug delivery pumps (e.g., insulin pumps or medication infusion pumps).\n* Metallic implants.\n* Intrauterine devices (IUDs) containing any type of metal.\n* Application over the growth plate area.\n* Severe or life-threatening disorders.\n* Pulmonary insufficiency.\n* Cardiac disorders \u002F Heart conditions.\n* Decompensated hemorrhagic conditions.\n* Decompensated blood coagulation disorders.\n* Malignant tumors \u002F Malignancy.\n* Fever.\n* Epilepsy.\n* Menstruation\n* Pregnant",{"count":120,"type":21},[91],"The goal of this non-randomized community clinical trial is to test how effective HIFEM (High Intensity Focused Electromagnetic) technology (BTL Emsella) is in strengthening pelvic floor muscles. The study focuses on first-time mothers who have recently given birth (postpartum) via vaginal delivery and are not showing symptoms of dysfunction.\n\nThe main question this study aims to answer is:\n\n\\- Can pelvic floor strength be restored after being exposed to weakening risk factors like pregnancy and childbirth?\n\nHow to study works; The researcher will compare two groups of women to see how their muscles recover:\n\n1. Those who receive the Emsella HIFEM treatment.\n2. Those who follow their natural recovery without the treatment.\n\nParticipant Journey:\n\n* Initial Check-up: Once the standard 6-week postpartum recovery period (quarantine) is over.\n* Eligibility: The researcher checks if participants meet the study criteria.\n* Decision: After receiving full information and signing a consent form, participants decide whether or not to undergo the treatment.\n* Final Results: A follow-up assessment is conducted 3 months after the first visit, regardless of whether the treatment was used.",[182],"Pelvic Floor Muscle Dysfunction",[184,185,186,187,188,189,190,156,191,192,193,194,195,196],"Puborectalis muscle","pelvic floor","transperineal ultrasound","posapartum","Electromagnetic therapy","female","incontinence","delivery","strain","ultrasonography","cesarean section","electroestimulation","pregnancy","2026-04-07",{"date":199,"type":41},"2026-04-14",{"date":166,"type":21},{"date":168,"type":21},{"name":47,"class":48},{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":117,"minAge":18,"maxAge":210,"enrollmentInfo":211,"targetDuration":4,"studyType":89,"phases":213,"briefSummary":214,"conditions":215,"keywords":217,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":230},"100602546","continuous-care-intervention-in-primary-care-to-improve-type-2-diabetes-control-in-terres-de-lebre-catalonia-100602546","NCT07124923","Continuous Care Intervention in Primary Care to Improve Type 2 Diabetes Control in Terres de l'Ebre, Catalonia","Effectiveness of a Continuous Care Intervention by the Endocrinology and Nutrition Service in Primary Care to Improve the Control of Type 2 Diabetes Mellitus in Terres de l'Ebre, Catalonia","Inclusion Criteria:\n\nEnrollment will begin in July 2025, aligned with the initiation of training sessions for healthcare professionals (physicians and nurses).\n\nEligible participants must:\n\n* Be adults (≥18 years old)\n* Have an active diagnosis of T2DM documented in the eCAP primary care electronic health record system\n* Have a duration of T2DM of at least 12 months as of January 2025\n\nExclusion Criteria:\n\n* Diagnosis of type 1 diabetes mellitus (T1DM)\n* T2DM managed by a specialist at the time of inclusion\n* Current treatment with systemic corticosteroids\n* Active neoplasia (malignancy)\n* Gestational diabetes\n* Pregnancy or breastfeeding\n* Diagnosis of MACA (advanced chronic disease with life expectancy \\\u003C1 year)\n* Complex chronic patients (CCP)\n* Diagnosis of dementia\n* Institutionalized patients or those residing in social healthcare facilities\n* Age over 90 years\n* Age under 18 years\n* Severe psychiatric illness (e.g., psychosis, bipolar disorder, major depression)\n* History of kidney transplant\n* Undergoing dialysis\n* History of alcohol or drug abuse","90 Years",{"count":212,"type":21},7792,[91],"This randomized, parallel-group clinical trial evaluates the effectiveness of a continuity of care intervention to improve metabolic control in adults with type 2 diabetes mellitus (T2DM) in the Terres de l'Ebre health region. The intervention, led by the Endocrinology Service at Hospital de Tortosa Verge de la Cinta (HTVC), involves structured, multidisciplinary training and feedback provided by endocrinologists and nurse educators to primary care professionals. Training modules combine theoretical and practical content focused on current diabetes management.\n\nPrimary care centers are randomized to intervention or control arms. Eligible participants are adult patients with an active diagnosis of T2DM for at least 12 months as of January 2025, registered in the eCAP system. All primary care professionals in intervention centers participate in the training.\n\nThe intervention is conducted over one year (July 2025-July 2026). Outcomes are assessed at baseline, 6, 12, and 24 months. The primary outcome is HbA1c; secondary outcomes include other health indicators, professional knowledge and engagement, and organizational variables. A qualitative component gathers professional input before and after the intervention to inform future implementation. All data are anonymized to ensure confidentiality.",[216],"Diabetes Mellitus Type 2",[218,219,220,221],"HbA1c","Primary Care","Continuity of Care","Training","2025-09-01",{"date":224,"type":41},"2025-09-08",{"date":226,"type":41},"2025-07-20",{"date":228,"type":21},"2027-07-20",{"name":47,"class":48},12,{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":117,"minAge":239,"maxAge":18,"enrollmentInfo":240,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":242,"conditions":243,"keywords":247,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":261},"100390972","early-detection-of-familial-hypercholesterolemia-in-children-100390972","NCT04370899","Early Detection of Familial Hypercholesterolemia in Children","Early Detection of Familial Hypercholesterolemia in Children in Tarragona Province","DECOPIN","Inclusion Criteria:\n\n* Children between 2 and 18 years of age.\n* LDL-C level above 135 mg\u002FdL\n* Previously, the pediatrician will have discarded secondary causes (hypercholesterolaemia such as hypothyroidism, nephrotic syndrome, diabetes, renal insufficiency).\n\nAfter confirmation that one of the parents has a genetic mutation (Lipoxip\u002FLiponext) or clinical diagnosis (DLCN ≥ 8), the child will be studied. The progenitor with hypercholesterolemia will be considered as an index case, in this way we will demonstrate the vertical transmission of the genetic disease.\n\nExclusion Criteria:\n\n* The child population under 2 and over the age of 18 and children.\n* Children with high cholesterol but by secondary causes.","2 Years",{"count":241,"type":21},400,"Heterozigous FH is an underdiagnosed disease in the paediatric population. Its early detection, would allow us to initiate lifestyle therapeutical changes and early pharmacological therapy if necessary. This is a key fact to reduce atherosclerosis progression and cardiovascular risk in adulthood. Moreover, it will allow, detecting the first and second degree affected relatives.",[244,245,246],"Familial Hypercholesterolemia","Familial Hypercholesterolemia - Heterozygous","Familial Hypercholesterolemia - Homozygous",[244,248,249,250,251,252],"Childhood","cardiovascular risk","lifestyle assessment","genetic disorder","LDL cholesterol","2025-04-17",{"date":255,"type":41},"2025-04-18",{"date":257,"type":41},"2013-03-14",{"date":259,"type":21},"2030-07-01",{"name":47,"class":48},2,{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":268,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":117,"minAge":18,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":89,"phases":272,"briefSummary":274,"conditions":275,"keywords":277,"overallStatus":282,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":291},"100565674","phase-4-evaluation-of-cardioverter-capacity-of-amiodarone-pre-electrical-cardioversion-in-persistent-atrial-fibrillation-100565674","NCT06645249","Evaluation of Cardioverter Capacity of Amiodarone Pre-electrical Cardioversion in Persistent Atrial Fibrillation","Multicenter, Randomized Clinical Trial to Evaluate the Cardioverter Capacity of Amiodarone Pre-electrical Cardioversion in Persistent Atrial Fibrillation","PERIVERSION","Inclusion Criteria:\n\n1. Patients ≥18 years old.\n2. Persistent atrial fibrillation (≥ 7 days duration).\n3. Referred for elective electrical cardioversion.\n4. Signing of the informed consent\n\nExclusion Criteria:\n\n1. Need of urgent electrical cardioversion\n2. Mean Heart rate \\<50 bpm\n3. Planned ablation \\< 1 month after ECV.\n4. Treatment with anti-arrhythmic drugs (IC, III) the last 7 days previous to inclusion (in the case of amiodarone on the 30 days previous to inclusion)\n5. Atrial fibrillation post-cardiac surgery\n6. New York Heart Association (NYHA) Class IV heart failure\n7. Left ventricular ejection fraction (LVEF) ≤30%\n8. History of thyroid disease (hyperthyroidism or hypothyroidism)\n9. Known hepatobiliary disease (acute hepatitis, cirrhosis...) or ALT\u002FAST \\> 3 x upper limit of normal (ULN)\n10. Allergy, intolerance, or known hypersensitivity to study medication\n11. Women of childbearing potential unwilling to use contraceptive measures\n12. Participation in another clinical trial involving investigational drugs\n13. Life expectancy less than 12 months\n14. Rheumatic mitral stenosis of any degree or severe mitral or aortic valve dysfunction.",{"count":271,"type":21},122,[273],"PHASE4","Phase: IV Population: Sample size= 122 patients; male and female; ≥ 18 y.o.; patients with persistent atrial fibrillation referred for electrical cardioversion; performed in Spain Number of Sites: 4 Study Duration: 15\u002F10\u002F2024 - 15\u002F5\u002F2026 Subject Participation Duration: 2-4 months (depending on the arm) Description of Agent or Intervention: amiodarone\n\nObjectives:\n\nPrimary: To compare the efficacy of amiodarone in pre-ECV reversal to sinus rhythm in a one-month impregnation regimen versus a 5-day regimen Secondary: 1) Identify days from initiation of pre-ECV amiodarone to reversion to SR using a mobile device paired to the mobile phone; 2) To compare the joint efficacy in the reversion to SR pre-ECV and in the maintenance of SR at 1 month after ECV of a one-month pre-ECV amiodarone impregnation regimen vs a 5-day regimen\n\nDescription of Study Design: Multicenter randomized open clinical trial. 122 Patients with persistent AF (≥7 days duration) electively referred for CVE will be included. Two amiodarone regimens administered pre-CVE will be compared evaluating their cardioverter efficacy. Patients will be randomized to 2 groups:\n\n1. Treatment impregnation with amiodarone starting one month before ECV (600 mg\u002Fday 1st week, 400 mg\u002Fday 2nd week and 200 mg\u002Fday thereafter until ECV).\n2. Treatment impregnation with amiodarone 800 mg\u002Fday started 5 days before ECV. Estimated Time to Complete Enrollment: 13 months",[276],"Atrial Fibrillation (AF)",[278,279,280,281],"Atrial fibrillation","Electrical cardioversion","amiodarone","Pharmacological cardioversion","NOT_YET_RECRUITING","2024-11-27",{"date":285,"type":41},"2024-12-02",{"date":287,"type":21},"2024-12-10",{"date":289,"type":21},"2026-10",{"name":47,"class":48},4,{"id":293,"slug":294,"hasResults":11,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":11,"sex":117,"minAge":18,"maxAge":4,"enrollmentInfo":299,"targetDuration":301,"studyType":22,"phases":4,"briefSummary":302,"conditions":303,"keywords":309,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":323},"100511010","the-impact-of-radiotherapy-on-oligometastatic-cancer-100511010","NCT05933876","The Impact of Radiotherapy on Oligometastatic Cancer","Stereotactic ABlative Radiotherapy (SABR) in Oligometastatic Cancer (OC): a Radiomics, Multi-omics, and Machine Learning Approach to Clinical Decision-making. the OC-SABR Multicentric Project","Inclusion Criteria:\n\n* Histologic confirmation of primary tumor: breast, prostate, lung, colorectal.\n* 18 years old or older.\n* Up to five metastases located in the bone, lung, node, liver or brain.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status Scale 0 or 1.\n\nExclusion Criteria:\n\n* Non-melanoma skin cancer.\n* Previous radiotherapy in the same anatomic location.\n* Presence of vascular collagen disease.\n* Pregnancy or lactation at the time of inclusion.",{"count":300,"type":21},2000,"5 Years","Metastases represent the most threatening challenge in cancer. One of the management strategies for patients with Oligometastatic Cancer (OC) is Stereotactic ABlative Radiotherapy (SABR). However, there are few studies, and there is no defined clinical standard, nor are the radiobiological mechanisms that contribute to treatment response well understood. The focus should be on generating evidence to guide the personalization of radiotherapy beyond solely technological and anatomical precision. This could be achieved by recollecting clinical and biological data from patients that undergo this treatment and analyzing them to ultimately predict, with the help of artificial intelligence, which patients will be the most beneficiary and improve their survival rate.",[304,305,306,307,308],"Metastasis","Metastatic Breast Cancer","Metastatic Prostate Cancer","Metastatic Colorectal Cancer","Metastatic Lung Cancer",[304,310,311,312,313,314],"Radiosurgery","Metabolomics","Radiomics","Multi-omics","Molecular subtypes","2024-11-14",{"date":317,"type":41},"2024-11-18",{"date":319,"type":41},"2022-12-01",{"date":321,"type":21},"2037-12-31",{"name":47,"class":48},21,{"id":325,"slug":326,"hasResults":11,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":11,"sex":117,"minAge":18,"maxAge":4,"enrollmentInfo":331,"targetDuration":333,"studyType":22,"phases":4,"briefSummary":334,"conditions":335,"keywords":339,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":49},"100481838","integrated-multi-omics-data-for-personalized-treatment-of-obesity-associated-fatty-liver-disease-100481838","NCT05554224","Integrated Multi-omics Data for Personalized Treatment of Obesity-associated Fatty Liver Disease","Integrated Multi-omics and Machine Learning-driven Personalized Treatment of Obesity-associated Fatty Liver Disease","Inclusion Criteria:\n\n* Body mass index greater or equal to 40 kg\u002Fm\\^2.\n* Body mass index between 35 and 40 kg\u002Fm\\^2 with high-risk comorbidities (diagnosis or treatment for hypertension, dyslipidemia, or type 2 diabetes mellitus).\n* Positive psychiatric evaluation.\n* Age greater or equal to 18 years old.\n\nExclusion Criteria:\n\n* Legal or illegal drug consumption, including alcohol.\n* Diagnosis of Hepatitis.\n* Current cancer diagnosis or treatment.\n* Clinical or analytical evidence of severe illness.\n* Clinical or analytical evidence of chronic or acute inflammation.\n* Clinical or analytical evidence of infectious diseases.\n* Clinical or analytical evidence of terminal illness.",{"count":332,"type":21},1104,"10 Years","The investigators seek to analyze the samples provided by patients with obesity-associated fatty liver disease at the multi-omics level and to integrate the results with clinical information, genotypic variants, and factors influencing inter-organ crosstalk. The main aim is to improve the interpretation of fatty liver disease associated with obesity and diabetes by developing predictive models built with algorithms from artificial intelligence. The challenge is to decipher the flow of information by exploring contributing factors, proximate causes of regulatory defects, and maladaptive responses that may promote therapeutic approaches.",[336,337,338],"NAFLD","Obesity, Morbid","Comorbidities and Coexisting Conditions",[340,341,342,343,344,345,311,346],"Weight loss","Bariatric surgery","Liver diseases","Mass spectrometry","Proteomics","Lipidomics","Transcriptomics","2024-11-11",{"date":349,"type":41},"2024-11-13",{"date":351,"type":41},"2008-06-25",{"date":353,"type":21},"2028-12-31",{"name":47,"class":48},{"id":356,"slug":357,"hasResults":11,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":361,"eligibilityCriteria":362,"healthyVolunteers":116,"sex":117,"minAge":18,"maxAge":363,"enrollmentInfo":364,"targetDuration":4,"studyType":89,"phases":365,"briefSummary":366,"conditions":367,"keywords":369,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":49},"100546462","circulating-microvesicles-regulating-metabolic-homeostasis-in-obesity-after-caloric-restriction-programs-100546462","NCT06395246","Circulating Microvesicles Regulating Metabolic Homeostasis in Obesity After Caloric Restriction Programs","The Usefulness of Circulating Microvesicles (host and Bacterial) in Regulating Metabolic Homeostasis in Obesity Randomized Study of Parallel Arms in Obese Patients Undergoing Caloric Restriction Diet Vs. Early Time-restricted Eating","TREV","Inclusion Criteria:\n\n1. age between 18 and 70 years old.\n2. BMI ranges between 27 and 40 kg\u002F m2.\n3. Absence of underlying pathology in medical and physical examination, except for those related to excess weight.\n4. Signature of the informed consent for participation in the study.\n\nExclusion Criteria:\n\n1. Serious systemic disease not related to obesity, such as cancer, kidney or severe liver disease.\n2. Systemic diseases with intrinsic inflammatory activity (autoimmune diseases such as rheumatoid arthritis and asthma).\n3. Pregnancy and lactation.\n4. Vegetarians or subjects subjected to an irregular diet.\n5. Patients with severe eating disorders.\n6. Patients with clinical symptoms and signs of infection in the previous month.\n7. Patients with chronic anti-inflammatory steroid treatments and\u002For nonsteroidal anti-inflammatory drugs.\n8. Recent antibiotic treatment.\n9. Uncontrolled alcoholism or drug abuse.\n10. Rotating or nocturnal shift workers.","70 Years",{"count":120,"type":21},[91],"The main aim of the present study is to evaluate the effectiveness of two dietary protocols: Daily Caloric Restriction (DCR) and Early Time-Restricted Feeding + DCR (eTRE) on metabolic homeostasis and the influence of circulating extracellular vesicles (EVs) as inter-organ communication elements in obese patients.",[368],"Obesity",[370,371,372,373,374,375,376,377],"obesity","extracellular vesicles","incretins","bile acids","short-chain fatty acids","time-restricted feeding","caloric restriction","brown fat","2024-10-03",{"date":380,"type":41},"2024-10-04",{"date":382,"type":41},"2024-05-20",{"date":384,"type":21},"2025-12-20",{"name":47,"class":48},{"id":387,"slug":388,"hasResults":11,"nctId":389,"briefTitle":390,"officialTitle":390,"acronym":391,"eligibilityCriteria":392,"healthyVolunteers":11,"sex":117,"minAge":145,"maxAge":363,"enrollmentInfo":393,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":394,"conditions":395,"keywords":400,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":261},"100550874","early-diagnosis-of-colorectal-cancer-based-on-a-non-invasive-metabolomics-profile-100550874","NCT06452745","Early Diagnosis of Colorectal Cancer Based on a Non-invasive Metabolomics Profile","EarlyCRC","Inclusion Criteria:\n\n* Patients with a positive FOBT test result from the Colorectal Cancer Early Detection Program and referred for a colonoscopy.\n\nExclusion Criteria:\n\n* Patients diagnosed with another primary neoplasm in the last 5 years, with the exception of carcinoma in situ of the cervix or non-melanoma skin cancer.\n* Patients with severe kidney disease stage IV (creatinine clearance \\\u003C 30 ml\u002Fmin).\n* Patients with severe active liver disease (hepatitis, cirrhosis).\n* Refusal to sign informed consent.",{"count":300,"type":21},"Colorectal cancer is the most frequent tumor in our environment if both sexes are considered together. Every year almost 800 cases are diagnosed in the districts of Tarragona. A little more than half of colorectal cancers are cured with surgery, with or without the addition of complementary treatments with chemotherapy and\u002For radiation therapy. Those who are not cured is because at the time of diagnosis the disease has already spread or they spread after having been treated surgically with curative intent.\n\nThe purpose of the EarlyCRC project is to determine whether metabolites (substances of low molecular weight) can be found in the urine and stool of patients with colorectal cancer or polyps that can be easily and cheaply differentiated (urine or stool analysis) between the patients affected by colorectal cancer or polyps, from healthy individuals. For the identification of these possible metabolites, the urine analysis will be performed using the usual techniques in metabolomics, which studies the existing metabolites in biological processes.",[396,397,398,399],"Colorectal Cancer","Colorectal Adenoma","Colorectal Polyp","Healthy",[401,402,403,404,405],"screening","urine","fobt","biomarkers","metabolomics","2024-09-30",{"date":408,"type":41},"2024-10-02",{"date":410,"type":41},"2019-07-20",{"date":412,"type":21},"2040-06-30",{"name":47,"class":48},{"id":415,"slug":416,"hasResults":11,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":420,"eligibilityCriteria":421,"healthyVolunteers":11,"sex":117,"minAge":18,"maxAge":4,"enrollmentInfo":422,"targetDuration":4,"studyType":89,"phases":424,"briefSummary":425,"conditions":426,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":430,"lastUpdatePostDateStruct":431,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":437,"locationsCount":49},"100402474","multimodal-prehabilitation-during-chemotherapy-in-patients-with-colorectal-liver-metastases-100402474","NCT04520737","Multimodal Prehabilitation During Chemotherapy in Patients With Colorectal Liver Metastases","Multimodal Prehabilitation During Neoadjuvant Chemotherapy in Patients With Colorectal Liver Metastases: a Randomized Controlled Trial","PREHABMET","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Written informed consent obtained from subject to participate in the study.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* ASA health class status IV-V\n* Mental conditions or disabling orthopedic and neuromuscular disease that prevent physical exercise or may compromise adherence to the program\n* Medical contraindication to perform exercise\n* Inability to obtain informed consent",{"count":423,"type":21},84,[91],"Liver resection is the only curative treatment for patients with colorectal liver metastases (CRLM). Most patients undergo chemotherapy (CT) before liver surgery. CT objectively decreases patient functional capacity. It has already been demonstrated that a structured training program carried out during the 4 weeks following CT, while the patient is waiting for liver resection, is able to return the functional capacity to baseline levels. Despite this, multimodal prehabilitation programs (MPP) during preoperative CT have not been evaluated or implemented.\n\nThe aim of this study is to investigate whether a 16-week MPP applied during and following CT in CRLM patients will result in a significant increase in physical fitness when compared to those that undergo MPP only during the 4-weeks, between the end of CT and liver resection.",[427,428,429],"Prehabilitation","Neoadjuvant Therapy","Liver Metastases","2024-06-27",{"date":432,"type":41},"2024-07-01",{"date":434,"type":41},"2021-02-01",{"date":436,"type":21},"2026-12-31",{"name":47,"class":48},""]